Zenas BioPharma Shares Plunge 19% as $287.5M Dilutive Convertible Note and Stock Offerings Are Priced
summarizeSummary
Zenas BioPharma's stock plummeted 19% after the company priced its concurrent public offerings of convertible senior notes and common stock, expecting to net approximately $287.5 million. This financing follows earlier announcements of proposed offerings and subsequent pricing details reported in SEC filings and news on March 26-27. The capital raise, which includes selling 5 million shares at $20 each, is crucial given the significant losses and a 'going concern' warning detailed in the company's recent 10-K, despite positive Phase 3 results for its lead candidate, obexelimab, reported on March 16. The substantial dilution, representing a material portion of the company's market capitalization, is driving investor concern and the sharp stock decline. Investors will now monitor the closing of these transactions on March 31 and the company's progress towards regulatory submissions and the commercial launch of obexelimab.
في وقت هذا الإعلان، كان ZBIO يتداول عند ١٧٫٧٦ US$ في NASDAQ ضمن قطاع Life Sciences، مع قيمة سوقية تقارب ١ مليار US$. تراوح نطاق التداول خلال 52 أسبوعًا بين ٦٫١١ US$ و٤٤٫٦٠ US$. تم تقييم هذا الخبر على أنه ذو معنويات سوقية سلبية وبدرجة أهمية ٨ من 10. المصدر: Dow Jones Newswires.